首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Design, synthesis, in-vitro, in-vivo and in-silico studies of pyrrolidine-2,5-dione derivatives as multitarget anti-inflammatory agents
【24h】

Design, synthesis, in-vitro, in-vivo and in-silico studies of pyrrolidine-2,5-dione derivatives as multitarget anti-inflammatory agents

机译:吡咯烷-2,5-二酮衍生物的设计,合成,体外,体内和硅研究,如多元抗炎剂

获取原文
获取原文并翻译 | 示例
           

摘要

In recent years, drug discovery paradigm has been shifted from conventional single target inhibition toward multitarget design concept. In current research, we have reported synthesis, in-vitro, in-vivo and acute toxicity determination of N-substituted pyrrolidine-2,5-dione derivatives as multitarget anti-inflammatory agents. We synthesized cycloalkyl, alkyl and aryl carbonyl derivatives by the Michael addition of ketones to N-substituted maleimides using self-assembled three component system as an organocatalyst. Anti-inflammatory potential of the compounds was determined by using different invitro assays, like cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase, albumin denaturation and anti-protease assays. Amongst the synthesized compounds, 13a-e series of compounds showed inhibition in low micromolar to submicromolar ranges. These compounds also demonstrated COX-2 selectivity. Compound 13e with IC50 value 0.98 mu M and SI of 31.5 emerged as the most potent inhibitor of COX-2. Based on in-vitro results, in-vivo anti-inflammatory investigations were performed on compounds 3b and 13e via carrageenan induced paw edema test. The possible mode of action of compounds 3b and 13e were ascertained with various mediators like histamine, bradykinin, prostaglandin and leukotriene. In-vivo acute toxicity study showed the safety of synthesized compounds up to 1000 mg/kg dose. The selectivity of the compounds against cyclooxygenase isoforms was supported by docking simulations. Selective COX-2 inhibitors showed significant interactions with the amino acid residues present in additional secondary COX-2 enzyme pocket. Furthermore, in-silico pharmacokinetic predictions confer the drug-like characteristics. (C) 2019 Elsevier Masson SAS. All rights reserved.
机译:近年来,药物开发模式已经从传统的单一目标向抑制多目标的设计理念转变。在目前的研究中,我们已经报道合成,在体外,在体内的N-取代的吡咯烷-2,5-二酮衍生物作为多目标抗炎剂的和急性毒性测定。我们使用自组装三个组分体系作为有机催化剂合成的环烷基,烷基和芳基羰基衍生物通过迈克尔加成酮与N-取代的马来酰亚胺。的化合物的抗炎潜力是通过使用不同的体外测定法,如环加氧酶1,环氧合酶-2和5-脂氧合酶,白蛋白变性和抗蛋白酶测定法测定。之间的合成的化合物和13a-E系列化合物显示抑制在低微摩尔至亚微摩尔的范围。这些化合物也显示出COX-2的选择性。用IC 50值0.98微米和31.5 SI化合物13E成为COX-2的最有效的抑制剂。基于体外结果,在体内抗炎调查是对化合物3B和13e通过角叉菜胶诱导的爪水肿试验进行。图3b和13e分别与确定各种递质等组胺,缓激肽,前列腺素和白三烯化合物的作用的可能模式。的体内急性毒性研究表明合成的化合物的高达1000毫克/公斤剂量的安全性。对环加氧酶同工型的化合物的选择性通过对接模拟支持。选择性COX-2抑制剂显示与存在于额外的第二COX-2酶口袋的氨基酸残基显著相互作用。此外,在计算机芯片的药代动力学预测赋予的药物样特性。 (c)2019年Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号